Invest Securities confirms its Buy rating on Valbiotis shares, and raises its target price from €10.3 to €12.3

Last night, the company announced the "broad success" of a Phase II/III clinical trial on a treatment for diabetes. This 3-year "clinical adventure" achieved its primary endpoint of reducing fasting glycemia "with high statistical significance", as Invest points out.

Despite the absence of exhaustive data (the full report on all data is expected this summer), the success of the study is very positive and will trigger a milestone payment of 4 million Swiss francs from Nestlé Health Science (NHS) as part of the strategic global partnership.

"This clinical success significantly strengthens the Group's credibility and validates the strategy", underlines Invest Securities.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.